Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi will take a 12% stake in Alnylam for $700 million in a transformative deal that revalidates the biotech’s RNAi technology platform after the company lost important big pharma partners three years ago. The announcement Jan. 13 kicked off the opening of the JP Morgan Healthcare conference.